Rare diseases
Investigational molecules
Locations
Building 37, 20892, United States
Clinical research in stage III colon adenocarcinoma with deficient mismatch repair focuses on adjuvant treatment strategies for patients with surgically treated disease. The sponsor’s activity in this area centers on colon cancer recurrence prevention and post-operative disease control.
The trial landscape reflects interest in improving outcomes for patients with resected colorectal malignancy, particularly where molecular features such as dMMR shape treatment selection.
National Cancer Institute runs clinical trials in conditions such as Adenocarcinoma of colon, Colon cancer stage III, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on Atezolizumab with FOLFOX for Stage III Colon Cancer with Deficient DNA Mismatch Repair
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
